Tradestie Institutional Equity Comparison Engine

ALNY vs REGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ALNY counters with relative strength in Valuation. Fundamentally, ALNY trades at 15.0x Forward P/E with 19.5% operating margin (+16.7% YoY revenue) versus REGN at 14.9x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, ALNY sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ALNY
ALNY 15.0x vs REGN 14.9x Fwd P/E
Growth & Margin Winner REGN
Op Margin 19.5% vs 30.4% ยท YoY +16.7% vs +36.3%
Momentum & Technical Winner REGN
1Y -68.0% vs +27.3% ยท 52W Pos 0% vs 83%
Options & Structure Winner REGN
BREAKDOWN (34th %ile IV) vs CONSOLIDATION (6th %ile IV)
ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$147.82
-1.06% 1D
Market Cap $20.0B
1M Return -34.33%
1Y Return -68.03%
Forward P/E 15.0x
Unified AI Score
50.9 / 100 HOLD
Tech 45.0 Fund 64.0 Flow 67.0 Mom 55.0
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
1M Return +14.61%
1Y Return +27.3%
Forward P/E 14.9x
Unified AI Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ALNY -68.03% REGN +27.3% Spread: +95.33 pp (REGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ALNY Revenue REGN Revenue ALNY Op. Margin REGN Op. Margin Margin Edge
FY2018 $70M $5.15B -1087.6% 49.3% REGN
FY2019 $220M $6.56B -427.5% 33.7% REGN
FY2020 $490M $8.50B -168.1% 42.1% REGN
FY2021 $840M $16.1B -83.9% 55.7% REGN
FY2022 $1.04B $12.2B -75.7% 38.9% REGN
FY2023 $1.83B $13.1B -15.4% 30.9% REGN
FY2024 $2.25B $14.2B -7.9% 28.1% REGN
FY2025 $3.71B $14.3B 13.5% 24.9% REGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ALNY (4) vs REGN (6)
Institutional Metric ALNY REGN Criterion Row Winner
Market Capitalization Scale $20.0B $97.8B Larger Scale REGN
Trailing P/E Ratio Valuation 7.5x 20.9x Lower Multiple ALNY
Forward P/E Ratio Valuation 15.0x 14.9x Lower Multiple REGN
Revenue Growth (YoY) Growth +16.7% +36.3% Higher Growth REGN
Operating Margin (TTM) Profitability 19.5% 30.4% Higher Margin REGN
Net Profit Margin Profitability 52.8% 28.5% Higher Margin ALNY
Return on Equity (ROE) Capital Efficiency 138.1% 14.9% Higher ROE ALNY
52-Week Range Position Momentum 0% ($147โ€“$477) 83% ($592โ€“$992) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.55ฮฒ ยท 94% Vol 0.32ฮฒ ยท 55% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 50.9 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite ALNY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ALNY vs REGN Buy Guide
ALNY BREAKDOWN
55d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ALNY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
55d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ALNY nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.